Kinetics of transperitoneal tissue-type plasminogen activator absorption

被引:11
|
作者
Holmdahl, L
Eriksson, E
Rippe, B
Risberg, B
机构
[1] UNIV LUND HOSP,DEPT NEPHROL,S-22185 LUND,SWEDEN
[2] LUND UNIV,MALMO GEN HOSP,DEPT SURG,S-21401 MALMO,SWEDEN
关键词
D O I
10.1016/S0268-9499(05)80069-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Peritoneal hypofibrinolysis has been suggested to be a central denominator in the formation of postoperative adhesions. Topical application of tissue-type plasminogen activator (t-PA) has been demonstrated to reduce adhesion formation, but the absorption of t-PA is not known. The aim of the present study was to determine the absorptive kinetics of t-PA by injecting varying doses of t-PA in intraperitoneally (i.p.) in rats. Plasma elimination was investigated in another set of experiments, where the same doses were injected intravenously (i.v.), The concentrations of t-PA in plasma were dose-dependent after both administrations, and at three and six hours the t-PA concentration in plasma was significantly higher after i.p. [64 (12.8) ng/mL (40 mu g dose)] and [297.6 (6.7) (400 mu g dose)] then after i.v. [27.9 (15.8) (40 mu g dose)] and [127.0 (35.0) (400 mu g dose)] (P<0.05). Uptake rate of t-PA from the peritoneal cavity was 2.4-6.2 mu L/min, which is compatible with peritoneal lymph flow, Plasma clearance was rapid after an i.v. injection (3.3-5.7 mL/min), and slower (0.8-1.7 mL/min) after i.p. administration, indicating a greater availability of t-PA when given i.p. To increase abdominal fibrinolytic capacity without affecting systemic fibrinolysis, a slow-release form of t-PA has to be used. The finding that i.p. administration gave rise to prolonged elevation of plasma concentration as compared to an i.v. injection may have some therapeutic implications in thrombolysis.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 50 条
  • [21] LAMININ INTERACTS WITH PLASMINOGEN AND ITS TISSUE-TYPE ACTIVATOR
    SALONEN, EM
    ZITTING, A
    VAHERI, A
    FEBS LETTERS, 1984, 172 (01) : 29 - 32
  • [22] HETEROGENEITY OF HUMAN TISSUE-TYPE PLASMINOGEN-ACTIVATOR
    OPDENAKKER, G
    BOSMAN, F
    DECOCK, B
    CABEZAARVELAIZ, Y
    VANDAMME, J
    BILLIAU, A
    FEBS LETTERS, 1988, 238 (01) : 129 - 134
  • [23] INHIBITION OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR BY PENICILLINS
    HIGAZI, A
    MEYER, M
    JOURNAL OF CLINICAL CHEMISTRY AND CLINICAL BIOCHEMISTRY, 1988, 26 (06): : 380 - 380
  • [24] CORONARY THROMBOLYSIS WITH TISSUE-TYPE PLASMINOGEN-ACTIVATOR
    ROBBINS, G
    NEW ENGLAND JOURNAL OF MEDICINE, 1984, 310 (23): : 1534 - 1535
  • [25] An endothelial storage granule for tissue-type plasminogen activator
    Emeis, JJ
    vandenEijndenSchrauwen, Y
    vandenHoogen, CM
    dePriester, W
    Westmuckett, A
    Lupu, F
    JOURNAL OF CELL BIOLOGY, 1997, 139 (01): : 245 - 256
  • [26] ORIGINS OF THE SPECIFICITY OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR
    DING, L
    COOMBS, G
    STRANDBERG, L
    NAVRE, M
    COREY, D
    MADISON, E
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1134 - 1134
  • [27] Tissue-type plasminogen activator deficiency exacerbates arthritis
    Yang, YH
    Carmeliet, P
    Hamilton, JA
    JOURNAL OF IMMUNOLOGY, 2001, 167 (02): : 1047 - 1052
  • [28] The End of Tissue-Type Plasminogen Activator's Reign?
    Derraz, Imad
    STROKE, 2022, 53 (08) : 2683 - 2694
  • [29] Role of tissue-type plasminogen activator in bone repair
    Kawao, Naoyuki
    Tamura, Yukinori
    Okumoto, Katsumi
    Yano, Masato
    Okada, Kiyotaka
    Matsuo, Osamu
    Kaji, Hiroshi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2014, 124 : 117P - 117P
  • [30] CLEARANCE RECEPTORS FOR TISSUE-TYPE PLASMINOGEN-ACTIVATOR
    CAMANI, C
    KRUITHOF, EKO
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 1994, 60 (02) : 97 - 109